摘要
转移性去势抵抗性前列腺癌(mCRPC)是一种恶性程度高的晚期前列腺肿瘤,其致死率高、治疗难度高,困扰着全世界的男性患者和医生。免疫治疗是近年来mCRPC治疗的研究热点,本文将从免疫治疗的理论基础到临床治疗应用,全面地介绍其现在的发展与未来的展望。
Metastatic castration-resistant prostate cancer(mCRPC)is a kind of highly malignant advanced prostate carcinoma,whose high fatality rate and low cure rate bother the worldwide male patients and doctors.In the last few years,immunotherapy has become an important cancer treatment modality.This article reviews the recent progress and future direction of the modern immunotherapy from the theoretical basis to clinical application.
作者
凌乐
刘博
刘继红
Ling Le;Liu Bo;Liu Jihong(Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Institute of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2020年第12期2185-2188,共4页
Chinese Journal of Experimental Surgery
基金
国家自然科学基金(81902619)。
